Immunic(IMUX) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), Immunic (IMUX) and Cipher Pharmaceuticals (OtherCPHRF)
TipRanksMar 20 08:00 ET · Ratings
Immunic Management to Meet Virtually With Piper Sandler
TipRanksMar 18 06:50 ET
Immunic Provides MS Research Update – ICYMI | NASDAQ:IMUX
Proactive InvestorsMar 14 16:07 ET
Immunic to Participate in Scientific and Investor Conferences in March
PR NewswireMar 3 06:30 ET
Biotechs Challenge Big Pharma With New Oral Weight Loss Therapies | NASDAQ:IMUX
Proactive InvestorsFeb 28 11:40 ET
Immunic to Highlight Vidofludimus Calcium's Potential as MS Therapy at Upcoming Forum | NASDAQ:IMUX
Proactive InvestorsFeb 26 08:40 ET

Comments

Jaguar8

Feb 26 20:28

NEWS

$Immunic (IMUX.US)$
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Wednesday, 26th February at 6:30 am
– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models –
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
NEW YORK, Feb. 26, 2025 /PRNewswi...

Teddy123

Feb 26 19:38

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

$Immunic (IMUX.US)$
Can Immunic's MS Drug Protect Neurons? New Data Reveals Promising Mechanism Ahead of Critical Trial Results

Teddy123

Feb 20 20:49

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

$Immunic (IMUX.US)$
Oral GLP-1 Breakthrough? New Drug Shows 250% Increase in Weight Loss Hormone

Trytosaveabit

Feb 20 20:35

update

$Immunic (IMUX.US)$ Reuters· 3 mins ago
Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Jaguar8

Feb 20 20:31

NEWS

$Immunic (IMUX.US)$
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
NEWS PROVIDED BY
Feb 20, 2025, 07:30 ET
Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready –
– Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinica...

1

IMUX Immunic

Trade Overview

Capital Trend

News

Comments

Market Insights